Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.00% | 205.10 | 1.2% | $477.70m | |
| GILD | Gilead Sciences, Inc. | 0.91% | 75.51 | 0.9% | $401.46m | |
| BIIB | Biogen Inc. | 1.22% | 345.41 | 1.3% | $352.23m | |
| CELG | Celgene Corporation | -0.66% | 87.72 | 1.2% | $341.18m | |
| ILMN | Illumina, Inc. | 0.52% | 358.16 | 3.5% | $248.76m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 0.78% | 390.28 | 2.6% | $232.51m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -0.24% | 180.08 | 1.9% | $168.98m | |
| EXAS | Exact Sciences Corporation | 1.72% | 76.28 | 25.3% | $162.68m | |
| SRPT | Sarepta Therapeutics, Inc. | -3.43% | 147.59 | 16.4% | $129.44m | |
| A | Agilent Technologies, Inc. | -0.58% | 70.72 | 1.5% | $124.93m | |
| VKTX | Viking Therapeutics, Inc. | -4.06% | 18.20 | 0.9% | $115.92m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -2.10% | 121.99 | 2.0% | $114.40m | |
| NKTR | Nektar Therapeutics | 0.96% | 59.00 | 5.6% | $106.74m | |
| BMRN | BioMarin Pharmaceutical Inc. | -2.55% | 97.84 | 4.4% | $97.41m | |
| ALNY | Alnylam Pharmaceuticals, Inc | -0.67% | 94.57 | 9.7% | $93.14m |
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in December 2013 and is headquartered in Norwood, MA.